Sangamo Therapeutics Inc (SGMO)

Dec 20, 2024

Astellas and Sangamo sign capsid deal for neurological diseases - MSN

Dec 20, 2024

Dec 20, 2024

Astellas partners with Sangamo on cutting-edge gene therapy - The Pharma Letter

Dec 20, 2024

Dec 19, 2024

Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development (NASDAQ:SGMO) - Seeking Alpha

Dec 19, 2024

Dec 19, 2024

Sangamo and Astellas link up in a $1.32B AAV deal - BioWorld Online

Dec 19, 2024

Dec 19, 2024

HC Wainwright Reiterates Buy Rating for Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat

Dec 19, 2024

Dec 19, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Shares Gap UpHere's What Happened - MarketBeat

Dec 19, 2024

Dec 19, 2024

Sangamo stock gains on Astellas licensing deal (SGMO:NASDAQ) - Seeking Alpha

Dec 19, 2024

Dec 19, 2024

Sangamo inks $20M gene therapy deal with Astellas; shares rally - Investing.com

Dec 19, 2024

Dec 19, 2024

Sangamo Shares Rally Premarket on License Deal With Astellas - MarketWatch

Dec 19, 2024

Dec 19, 2024

Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga

Dec 19, 2024

Dec 19, 2024

Astellas hopes Sangamo's capsid can get gene therapies across the blood-brain barrier - FirstWord Pharma

Dec 19, 2024

Dec 19, 2024

Regarding Sangamo - substack.com

Dec 19, 2024

Dec 19, 2024

Sangamo Therapeutics, Inc. and Astellas Pharma Inc. Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases - Marketscreener.com

Dec 19, 2024

Dec 19, 2024

Sangamo Therapeutics Lands Major $1.3B Gene Therapy Deal with Astellas for Brain Disease Treatment - StockTitan

Dec 19, 2024

Dec 18, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Shares Down 5%Time to Sell? - MarketBeat

Dec 18, 2024

Dec 17, 2024

Sangamo surges 24% after Roche ends development of hemophilia A gene therapy - MSN

Dec 17, 2024

Dec 17, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Shares Gap DownShould You Sell? - MarketBeat

Dec 17, 2024

Dec 16, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Upgraded by StockNews.com - MarketBeat

Dec 16, 2024

Dec 16, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Trading Up 25.5%Still a Buy? - MarketBeat

Dec 16, 2024

Dec 16, 2024

Sangamo shares surge on Roche gene therapy withdrawal By Investing.com - Investing.com Canada

Dec 16, 2024

Dec 14, 2024

Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces hurdles - Investing.com

Dec 14, 2024

Dec 13, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Upgraded to "Buy" at Truist Financial - MarketBeat

Dec 13, 2024

Dec 10, 2024

The Analyst Landscape: 6 Takes On Sangamo Therapeutics - Benzinga

Dec 10, 2024

Dec 10, 2024

Sangamo Biosciences’ Legal Victory and Hemophilia Trial Success - TipRanks

Dec 10, 2024

Dec 09, 2024

Jacobs Levy Equity Management Inc. Lowers Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat

Dec 09, 2024

Dec 08, 2024

mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.

Dec 08, 2024

Dec 08, 2024

Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30% - Simply Wall St

Dec 08, 2024

Dec 06, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Downgraded to Hold Rating by StockNews.com - MarketBeat

Dec 06, 2024

Dec 01, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Wasatch Advisors LP - MarketBeat

Dec 01, 2024

Nov 30, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update - MarketBeat

Nov 30, 2024

Nov 23, 2024

GSA Capital Partners LLP Sells 587,544 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat

Nov 23, 2024

Nov 21, 2024

Sangamo stock climbs 12% post-market on FDA update for ST-503 - MSN

Nov 21, 2024

Nov 21, 2024

Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online

Nov 21, 2024

Nov 20, 2024

Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts - Simply Wall St

Nov 20, 2024

Nov 19, 2024

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - BioSpace

Nov 19, 2024

Nov 19, 2024

Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment - Marketscreener.com

Nov 19, 2024

Nov 19, 2024

Sangamo's Novel Gene Therapy for Chronic Pain Gets FDA Clearance for Clinical Trials | SGMO Stock News - StockTitan

Nov 19, 2024

Nov 18, 2024

What is HC Wainwright's Forecast for SGMO FY2024 Earnings? - MarketBeat

Nov 18, 2024

Nov 15, 2024

FY2028 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat

Nov 15, 2024

Nov 15, 2024

Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 15, 2024

Nov 14, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays - MarketBeat

Nov 14, 2024

Nov 14, 2024

Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces challenges, opportunities - Investing.com Canada

Nov 14, 2024

Nov 13, 2024

Sangamo: Q3 Earnings Snapshot - Marketscreener.com

Nov 13, 2024

Nov 13, 2024

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates - MSN

Nov 13, 2024

Nov 13, 2024

Earnings call: Sangamo Therapeutics reports progress in gene therapies By Investing.com - Investing.com Australia

Nov 13, 2024

Nov 13, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Nov 13, 2024

Earnings call: Sangamo Therapeutics reports progress in gene therapies - Investing.com India

Nov 13, 2024

Nov 13, 2024

Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Nov 13, 2024